



Date: September 4, 2013

Federal Communications Commission
Authorization and Evaluation Division

Confidentiality Request regarding application for certification of FCC ID: QYY-51360

Pursuant to Sections 0.457 and 0.459 of the Commission's Rules, we hereby request confidential treatment of information accompanying this application as outlined below:

Exhibit Type

Block Diagram
Schematics
Operational Description

File Name

QYY-51360 BlkDia.pdf
QYY-51360 Schem.pdf
QYY-51360 OpDes.pdf

The above materials contain trade secrets and proprietary information not customarily released to the public. The public disclosure of these materials may be harmful to the applicant and provide unjustified benefits to its competitors.

The applicant understands that pursuant to Section 0.457 of the Rules, disclosure of this application and all accompanying documentation will not be made before the date of the Grant for this application.

Pursuant to DA04-1705 June 15, 2004 of the Commission's public notice, we also require temporary confidential treatment of information accompanying this application as outlined below:

Exhibit Type

Internal Photos

File Name

QYY-51360 IntPho.pdf

Temporary confidentiality from public disclosure is important for Nova Biomedical from a commercial perspective. It enables the company to complete its development and regulatory efforts prior to introducing the product to the marketplace. Releasing information on the product via the FCC website prior to formal market introduction can be confusing to our customers and the medical community, and places the company at a competitive disadvantage.

Sincerely,

A handwritten signature in dark ink, appearing to read "James S. Sidwell", written over a horizontal line.

Dr. James S. Sidwell
Vice President, Diabetes R&D